DALLAS, Oct. 31, 2023 /PRNewswire/ -- Match Group (NASDAQ: MTCH) posted its third quarter 2023 shareholder letter on the investor relations section of its website at https://ir.mtch.com. As announced previously, the Company will host a conference call tomorrow, Wednesday, November 1, 2023, at 8:30 a.m. Eastern Time (ET) to discuss the results. The live webcast and replay will be open to the public at https://ir.mtch.com.
About Match Group
Match Group (NASDAQ: MTCH), through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Our global portfolio of brands includes Tinder®, Hinge®, Match®, Meetic®, OkCupid®, Pairstm, PlentyOfFish®, Azar®, Hakunatm, and more, each built to increase our users' likelihood of connecting with others. Through our trusted brands, we provide tailored services to meet the varying preferences of our users. Our services are available in over 40 languages to our users all over the world.
ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of information and communication technology solutions, today announced that it was honored with 2023 Climate...
During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture,...
Hikvision has released its full-year 2023 financial results, reporting a total revenue of RMB 89.34 billion, up 7.42% year-over-year. Net profit attributable to shareholders of the company was RMB 14.11 billion, achieving a year-over-year (YoY)...
DTEN, a leading provider of video conferencing solutions, is proud to announce that their flagship All-in-One solution, the DTEN D7X series, is now available to purchase in South Korea after it has successfully passed the rigorous certification...
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...
During the second phase of the 135th China Import and Export Fair ("Canton Fair" or "the Fair"), a significant memorandum of cooperation was signed between the Fair and the Guangzhou Branch of the National Archives of Publications and Culture,...
